NASDAQ:FLGT - Fulgent Genetics Stock Price, Forecast & News

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics Inc (NASDAQ:FLGT) issued its quarterly earnings results on Monday, November, 4th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.08. The company earned $10.35 million during the quarter, compared to analysts' expectations of $8.48 million. Fulgent Genetics had a negative return on equity of 0.16% and a negative net margin of 3.52%. View Fulgent Genetics' Earnings History.

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Fulgent Genetics.

2 brokerages have issued twelve-month price targets for Fulgent Genetics' stock. Their forecasts range from $12.30 to $12.30. On average, they expect Fulgent Genetics' stock price to reach $12.30 in the next year. This suggests that the stock has a possible downside of 6.5%. View Analyst Price Targets for Fulgent Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.

News articles about FLGT stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fulgent Genetics earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Fulgent Genetics.

Fulgent Genetics saw a decrease in short interest in the month of November. As of November 29th, there was short interest totalling 182,900 shares, a decrease of 20.3% from the November 14th total of 229,400 shares. Based on an average daily volume of 252,500 shares, the days-to-cover ratio is currently 0.7 days. Currently, 2.8% of the company's stock are short sold. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Cancer Genetics (CGIX), Avant Diagnostics (AVDX), CBA Florida (CBAI) and OpGen (OPGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Baozun (BZUN), Crispr Therapeutics (CRSP), Baidu (BIDU), Zynerba Pharmaceuticals (ZYNE), Intellia Therapeutics (NTLA), InVitae (NVTA), Catalyst Pharmaceuticals (CPRX), Alibaba Group (BABA), Canopy Growth (CGC) and Corbus Pharmaceuticals (CRBP).

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Raymond James Trust N.A. (2.70%), Essex Investment Management Co. LLC (0.66%), Mutual Advisors LLC (0.57%) and Russell Investments Group Ltd. (0.01%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Mutual Advisors LLC and Essex Investment Management Co. LLC. View Insider Buying and Selling for Fulgent Genetics.

FLGT stock was bought by a variety of institutional investors in the last quarter, including Raymond James Trust N.A. and Russell Investments Group Ltd.. View Insider Buying and Selling for Fulgent Genetics.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $13.15.

Fulgent Genetics has a market capitalization of $246.04 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]